<DOC>
	<DOCNO>NCT02404038</DOCNO>
	<brief_summary>This study enrol sexually active , healthy girl age 16-17 ass compare acceptability preference monthly vaginal ring , bi-monthly injectable contraception daily dose oral contraception , proxy female-controlled ARV-based HIV prevention method .</brief_summary>
	<brief_title>A Study Evaluate Acceptability Preference Contraceptive Options Proxy HIV Prevention Methods</brief_title>
	<detailed_description>The family plan field show importance provide sufficient choice meet individual ' change need preference , demonstrate diversify delivery mode dose option key expand acceptability , use continuation contraceptive product . It yet clear extent choice preference mode delivery play biomedical HIV prevention world . It may possible closely associated behavioural component decision use , uptake , consistent adherence prevention product hinge sense particular modality prefer suit individual compare modality . Vaginal ring , pill , injectables already proven successful field contraception , therefore may act surrogate range HIV prevention delivery option may help meet different sexual reproductive health concern woman . A good understanding population adolescent seek contraception also help researcher understand acceptability feasibility , well adherence similar mode delivery HIV prevention option . By use contraceptive method proxy available female-controlled HIV prevention delivery method , microbicides PrEP , propose examine detail , acceptability surrogate adolescent woman ; preference mode delivery ; adherence barrier facilitator thereof product . Three contraceptive option use study emulate mode delivery currently develop HIV prevention option : ( 1 ) monthly vaginal ring ( NuvaRing ) , ( 2 ) bi-monthly injectable contraception ( Nuristerate ) ( 3 ) daily dose oral contraception ( Triphasil Nordette ) . This open-label , randomize crossover study 150 sexually active female adolescent ( &gt; 16 &lt; 18 year ) recruit , parental consent , randomly assign monthly vaginal ring , bi-monthly injectable contraception , daily dose oral contraception baseline . After 4 month , participant crossover , ensure participant use vaginal ring , either oral contraceptive bi-monthly injectable contraceptive throughout course study . Participants follow total 8 month . Upon enrollment participant randomly assign 1:1:1 ratio one three study arm ( 50 participant per arm ) : Arm 1/Group A : Participants receive injectable contraceptive every 8 week 4 month period . Arm 2/Group B : Participants receive contraceptive intravaginal NuvaRing insert every 28 day ( remove 21 day 28 day insertion ) 4 month period Arm 3/Group C : Participants supply oral contraceptive require take daily tablet 21 day month placebo tablet day 22 28 month , 4 month period . After 4 month , participant Group A Group C assign Group B ; participant Group B allow select either Groups A Group C , ensure participant use vaginal ring , either oral contraceptive bi-monthly injectable contraceptive . Participants attend follow-up visit every 8 week throughout duration study . Those participant receive oral contraceptive intravaginal ring therefore receive 8 week ' product supply visit . At visit preference / acceptability , sexual behaviour adherence study product assess use mainly quantitative measure general attitude experience use assessed focus group discussion end study .</detailed_description>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>1 . Age 16 17 year ( inclusive ) screening , verify per study site SOPs . 2 . Able willing provide write informed consent guardian able willing provide write informed consent screen take part study . 3 . Report sexually active , defined penetrative vaginal sex last 90 day . 4 . ( For potential participant currently use method hormonal contraception ) Reports within 30 day less needing new supply contraception ; agree terminate current method contraception ; indicate willingness use contraceptive option assign study . 5 . Able willing provide adequate locator information , define site SOPs . 6 . HIVuninfected base test perform study staff screen enrollment . 7 . Has negative pregnancy test screen enrollment per participant report , intend become pregnant next 8 month . 8 . Agrees use condom , addition assign contraception option , duration study 9 . Does report intention relocate study area course study . 10 . At Screening/ Enrollment , participant state willingness refrain insert nonstudy vaginal product object vagina , include limited , spermicide , diaphragm , contraceptive vaginal ring ( besides Nuvaring ) , vaginal medication , menstrual cup , cervical cap ( vaginal barrier method ) , douche , lubricant , sex toy ( vibrator , dildo , etc ) throughout duration study participation . 11 . Does job obligation would require long absence area ( &gt; 8 week time ) . 12 . Willing undergo studyrequired procedure . 13 . At screen enrollment , agree participate research study involve medical device vaginal product next 32 week 1 . Diagnosed pelvic inflammatory disease , sexually transmit infection ( STI ) reproductive tract infection ( RTI ) require treatment per current WHO guideline . Note : Otherwise eligible participant diagnose STI RTI screen offer treatment may enrol complete treatment symptom resolve . 2 . Urine dipstick protein glucose , &gt; 1+ . 3 . Any Grade &gt; 2 toxicity screening test assessment . 4 . Has condition , opinion investigator , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective . 5 . Known allergy sensitivity study product . 6 . Demonstrates intent desire conceive next 32 week . 7 . Appears psychologically unstable , intoxicated influence alcohol drug time inform consent . 8 . Has condition , opinion investigator/designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective . 9 . Has hormonal contraceptive implant device intrauterine contraceptive device .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>choice</keyword>
	<keyword>young woman</keyword>
	<keyword>adolescent girl</keyword>
	<keyword>preference</keyword>
</DOC>